CN115197202B - 一种ezh2共价抑制剂及其制备方法和应用 - Google Patents
一种ezh2共价抑制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN115197202B CN115197202B CN202210832077.XA CN202210832077A CN115197202B CN 115197202 B CN115197202 B CN 115197202B CN 202210832077 A CN202210832077 A CN 202210832077A CN 115197202 B CN115197202 B CN 115197202B
- Authority
- CN
- China
- Prior art keywords
- compound
- ezh2
- cancer
- alkyl group
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title claims abstract description 116
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title claims abstract description 114
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 229940125808 covalent inhibitor Drugs 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 136
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 239000003112 inhibitor Substances 0.000 claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 34
- 238000006243 chemical reaction Methods 0.000 claims description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 15
- 230000009471 action Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 4
- 238000006268 reductive amination reaction Methods 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 3
- 206010005969 Bone giant cell tumour Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims description 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000011143 bone giant cell tumor Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
- 239000005456 alcohol based solvent Substances 0.000 claims description 2
- 239000012670 alkaline solution Substances 0.000 claims description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 claims description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 28
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract description 22
- 230000035772 mutation Effects 0.000 abstract description 12
- 230000002018 overexpression Effects 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 238000010828 elution Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 239000007787 solid Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- FADJTYGNEWCCFM-UHFFFAOYSA-N 5-bromo-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methylbenzamide Chemical compound C=1C(Br)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 FADJTYGNEWCCFM-UHFFFAOYSA-N 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 14
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- IPITXYVHPYUULP-UHFFFAOYSA-N 5-bromo-3-[ethyl(oxan-4-yl)amino]-2-methylbenzoic acid Chemical compound C=1C(Br)=CC(C(O)=O)=C(C)C=1N(CC)C1CCOCC1 IPITXYVHPYUULP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101150090105 Ezh2 gene Proteins 0.000 description 6
- FJGLXTUCCQZCCR-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-phenylbenzamide Chemical compound CCN(C1CCOCC1)C1=CC(=CC(C(=O)NCC2=C(C)C=C(C)NC2=O)=C1C)C1=CC=CC=C1 FJGLXTUCCQZCCR-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010036115 Histone Methyltransferases Proteins 0.000 description 5
- 102000011787 Histone Methyltransferases Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 235000019750 Crude protein Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- NMLOSXSDLWFBKT-UHFFFAOYSA-N methyl 3-amino-5-bromo-2-methylbenzoate Chemical compound COC(=O)C1=CC(Br)=CC(N)=C1C NMLOSXSDLWFBKT-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 2
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 102000051614 SET domains Human genes 0.000 description 2
- 108700039010 SET domains Proteins 0.000 description 2
- 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- WCGGWVOVFQNRRS-UHFFFAOYSA-N dichloroacetamide Chemical compound NC(=O)C(Cl)Cl WCGGWVOVFQNRRS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000013037 reversible inhibitor Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WQAZDEYUFZDDKF-UHFFFAOYSA-N 3-(aminomethyl)-4,6-diethyl-1H-pyridin-2-one Chemical compound NCC=1C(NC(=CC=1CC)CC)=O WQAZDEYUFZDDKF-UHFFFAOYSA-N 0.000 description 1
- PCJPGNCABBDNJU-UHFFFAOYSA-N 3-(aminomethyl)-4,6-dimethyl-1h-pyridin-2-one Chemical compound CC1=CC(C)=C(CN)C(=O)N1 PCJPGNCABBDNJU-UHFFFAOYSA-N 0.000 description 1
- PAQRCBVGFAXTLI-UHFFFAOYSA-N 3-(aminomethyl)-4-ethyl-6-methyl-1h-pyridin-2-one Chemical compound CCC=1C=C(C)NC(=O)C=1CN PAQRCBVGFAXTLI-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IMQJERUFPGBLTJ-UHFFFAOYSA-N 4-(aminomethyl)-1-methyl-5,6,7,8-tetrahydro-2H-isoquinolin-3-one Chemical compound NCC=1C(NC(=C2CCCCC12)C)=O IMQJERUFPGBLTJ-UHFFFAOYSA-N 0.000 description 1
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 description 1
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 description 1
- 101001008816 Homo sapiens N-lysine methyltransferase KMT5A Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100225547 Mus musculus Ehmt2 gene Proteins 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 102100027771 N-lysine methyltransferase KMT5A Human genes 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000002273 Polycomb Repressive Complex 1 Human genes 0.000 description 1
- 108010000598 Polycomb Repressive Complex 1 Proteins 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 108700028341 SMARCB1 Proteins 0.000 description 1
- 101150008214 SMARCB1 gene Proteins 0.000 description 1
- 102100025746 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- SGCILHRPCZDQGD-UHFFFAOYSA-N methyl 5-bromo-2-methyl-3-(oxan-4-ylamino)benzoate Chemical compound COC(=O)C1=CC(Br)=CC(NC2CCOCC2)=C1C SGCILHRPCZDQGD-UHFFFAOYSA-N 0.000 description 1
- SLSYENZIHLMJNW-UHFFFAOYSA-N methyl 5-bromo-3-[ethyl(oxan-4-yl)amino]-2-methylbenzoate Chemical compound C=1C(Br)=CC(C(=O)OC)=C(C)C=1N(CC)C1CCOCC1 SLSYENZIHLMJNW-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种EZH2共价抑制剂及其制备方法和应用，属于化学医药领域。该EZH2共价抑制剂为式I所示化合物。该化合物能够与EZH2发生共价结合，对EZH2WT和EZH2MUT均展现出低纳摩尔水平的抑制活性，对由EZH2过表达或由EZH2突变导致的疾病均具有优良的治疗潜力；该化合物可有效抑制肿瘤细胞的增殖，洗脱后仍然发挥持续抑制活性，能够预防耐药性的产生，效果显著优于已上市的EZH2抑制剂EPZ6438；该化合物在异种移植瘤模型中的抗肿瘤活性的效果也显著优于已上市的EZH2抑制剂EPZ6438。本发明提供的化合物作为EZH2共价抑制剂，可以用来制备预防和治疗由EZH2过表达或由EZH2突变导致的疾病，为临床药物的开发和应用提供了新的选择。
Description
技术领域
本发明属于化学医药领域，具体涉及一种EZH2共价抑制剂及其制备方法和应用。
背景技术
组蛋白赖氨酸甲基转移酶EZH2是多梳家族蛋白PRC2复合物的催化组分，可通过催化组蛋白H3第27位赖氨酸(H3K27)发生三甲基化而抑制靶基因的表达。研究发现，相对正常组织来说，EZH2在多种癌组织(例如乳腺癌、前列腺癌、卵巢癌、宫颈癌、淋巴瘤等)中表达异常增高，且其表达越高，肿瘤恶性度越高，预后越差。
除了表达水平的异常，EZH2基因的突变也与肿瘤的发生发展密切相关。比如，研究发现22％的弥漫性大B细胞性淋巴瘤的生发中心、7％的滤泡性淋巴瘤以及12％～23％的脊髓发育不良和骨髓增生性疾病患者的体细胞中，均存在EZH2基因的突变。目前已经检测到的EZH2基因突变主要位于EZH2的SET结构域第641位酪氨酸(Y641N、F、S或H)、第677位丙氨酸突变为甘氨酸(alanine 677 glycin，A677G)和第687位丙氨酸突变为缬氨酸(alanine687 valine，A687V)。与EZH2的过表达不同，EZH2基因突变导致H3K27me3丰度在全基因组范围内显著上升。也就是说，EZH2过表达、EZH2基因突变都与许多肿瘤的发生发展密切相关，并与肿瘤的不良预后有关联。开发出能够有效抑制野生型EZH2和突变型EZH2的药物对治疗临床预防和治疗肿瘤具有重要意义。
目前，已经有多个靶向EZH2的小分子化合物进入临床。其中，已上市的EPZ6438作为一种有效的EZH2可逆抑制剂，能够浓度依赖性的降低野生型或SMARCB1突变细胞中总体H3K27Me3水平，并引起去除SMARCB1的MRT细胞系中强的抗增殖作用。但是，作为一种EZH2可逆抑制剂，EPZ6438存在以下问题：(1)EPZ6438对EZH2的作用强度不够，抑制活性有限；(2)EPZ6438的半衰期较短，给药剂量较大；(3)EPZ6438对EZH2靶蛋白难以产生持续抑制作用，易产生耐药。为了克服上述问题，亟需开发出一种对EZH2的作用强度更大，且不易产生耐药性的新EZH2抑制剂。
发明内容
本发明的目的在于提供一种EZH2共价抑制剂及其制备方法和应用。
本发明提供了式Ⅰ所示的化合物、其同位素标记化合物或其药学上可接受的盐：
其中，R1、R2、R3各自独立地选自H、C1-6烷基；或者，R1选自H、C1-6烷基，R2、R3连接形成5～8元饱和环烷基；
R4选自H、C1-6烷基；
R5选自未被取代或被取代基取代的以下基团：3～8元饱和环烷基、3～8元饱和杂环基；所述饱和杂环基中的杂原子选自N、O或S，杂原子个数为1～3个；所述取代基选自C1-6烷基；
L选自m选自0，1，2，3；n选自0，1，2，3；R8各自独立地选自氢、C1-6烷基；p选自0，1，2，3；
R6为可与半胱氨酸发生共价反应的基团；
R7选自H、C1-6烷基。
进一步地，所述化合物的结构如式II所示：
其中，R1、R2、R3各自独立地选自H、C1-3烷基；或者，R1选自H、C1-3烷基，R2、R3连接形成5～6元饱和环烷基；
R4选自H、C1-3烷基；
R7选自H、C1-3烷基；
n选自0，1，2，3；
R8选自氢、C1-3烷基；
X选自CO、SO2；
R9选自卤素；
R10、R11各自独立地选自H、卤素。
进一步地，所述化合物的结构如式III所示：
其中，R1、R2、R3各自独立地选自H、C1-3烷基；或者，R1选自H、C1-3烷基，R2、R3连接形成5～6元饱和环烷基；
R4选自H、C1-3烷基；
R7选自H、C1-3烷基；
n选自0，1，2，3；
R8选自氢、C1-3烷基；
Y选自CO、SO2。
进一步地，式I中，R1、R2、R3各自独立地选自H、C1-2烷基；或者R1选自H、C1-2烷基，R2、R3连接形成6元饱和环烷基；
和/或，R4选自H、C1-2烷基；
和/或，R5选自未被取代或被取代基取代的以下基团：5～6元饱和环烷基、5～6元饱和杂环基；所述取代基选自C1-6烷基；
和/或，L选自 和/或，R6选自
和/或，R7选自H、C1-2烷基。
进一步地，所述化合物选自如下结构：
本发明还提供了一种制备上述化合物的方法，所述方法包括以下步骤：
步骤1：化合物A与化合物B在还原剂的作用下进行还原胺化反应，得到化合物C；
步骤2：化合物C与化合物D在还原剂的作用下进行还原胺化反应，得到化合物E；
步骤3：化合物E进行水解反应，得到化合物F；
步骤4：化合物F与化合物G在偶联剂的作用下反应，得到化合物H；
步骤5：化合物H和化合物J在钯催化剂的作用下反应，得到式I所示化合物；
其中，R1-R7、L如上所述。
进一步地，步骤1中，所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠、硼氢化钠中的任意一种或两种以上的混合物；所述反应的溶剂为二氯乙烷、三氯甲烷、二氯甲烷中的任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤2中，所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠、硼氢化钠中的任意一种或两种以上的混合物；所述反应的溶剂为二氯乙烷、三氯甲烷、二氯甲烷中的任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤3中，所述水解反应是在碱溶液中进行的；所述碱为碳酸钠、氢氧化钠、氢氧化钾中任意一种或两种以上的混合物；所用碱溶液中的溶剂为醇类溶剂、水中的任意一种或两种的混合物；所述水解反应的温度为40～90℃；
步骤4中，所述偶联剂选自1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐、N-羟基-7-氮杂苯并三氮唑、1-羟基苯并三唑中任意一种或两种以上的混合物；所述反应的溶剂为二甲亚砜、N，N-二甲基甲酰胺、四氢呋喃、二氯甲烷中任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤5中，所述钯催化剂选自([1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物、醋酸钯或四(三苯基磷)钯)中任意一种或两种的混合物；所述反应的溶剂为二氧六环和水的混合溶液；所述反应的温度为90～110℃。
本发明还提供了一种药物组合物，它是以上述的化合物、其同位素标记化合物或其药学上可接受的盐为活性成分，加入药学上可接受的辅料或者辅助性成分制备而成的制剂。
本发明还提供了上述的化合物、其同位素标记化合物或其药学上可接受的盐在制备EZH2抑制剂中的用途。
进一步地，所述EZH2抑制剂为EZH2共价抑制剂。
进一步地，所述EZH2抑制剂为抑制野生型EZH2和/或突变型EZH2的药物。
进一步地，所述突变型EZH2包括A677G、A687V、Y641N、Y641F、Y641S、Y641H。
进一步地，所述EZH2抑制剂为预防和/或治疗癌症或自身免疫性疾病的药物。
进一步地，所述癌症包括脑癌、成胶质细胞瘤、白血病、淋巴瘤、乳腺癌、炎性乳腺癌、维尔姆斯瘤、尤因肉瘤、横纹肌肉瘤、室管膜瘤、成神经管细胞瘤、结肠癌、胃癌、膀肤癌、头颈癌、肾癌、肺癌、肝癌、黑素瘤、肾脏癌、卵巢癌、胰腺癌、前列腺癌、肉瘤、骨肉瘤、骨巨细胞瘤、甲状腺癌、宫颈癌；所述自身免疫性疾病包括银屑病或红斑狼疮。
关于本发明的使用术语的定义：除非另有说明，本文中基团或者术语提供的初始定义适用于整篇说明书的该基团或者术语；对于本文没有具体定义的术语，应该根据公开内容和上下文，给出本领域技术人员能够给予它们的含义。
本发明提供的化合物和衍生物可以根据IUPAC(国际纯粹与应用化学联合会)或CAS(化学文摘服务社，Columbus，OH)命名系统命名。
术语“烷基”是直链或支链的饱和烃基的基团。碳氢基团中碳原子含量的最小值和最大值通过前缀表示，例如，前缀Ca～b烷基表示任何含“a”至“b”个碳原子的烷基。
例如，C1-6烷基是指包含1-6个碳原子的直链或支链的烷基。C1-6烷基的实例包括但不限于甲基(C1)、乙基(C2)、正丙基(C3)、异丙基(C3)、正丁基(C4)、叔丁基(C4)、仲丁基(C4)、异丁基(C4)、正戊基(C5)、3-戊基(C5)、戊基(C5)、新戊基(C5)、3-甲基-2-丁基(C5)、叔戊基(C5)和正己基(C6)。
术语“环烷基”是指饱和或不饱和的环状烃取代基。例如，“3-8元饱和环烷基”指环碳原子数为3-8的饱和的环烷基。
术语“杂环基”指饱和或不饱和的环状烃取代基，且环状烃携带至少一个环杂原子(包括但不限于O、S或N)。例如，“3-8元饱和杂环基”指环原子数为3-8的饱和的杂环基。
术语“卤素”指氟、氯、溴或碘。
术语“药学上可接受的”指某载体、运载物、稀释剂、辅料，和/或所形成的盐通常在化学上或物理上与构成某药物剂型的其它成分相兼容，并在生理上与受体相兼容。
术语“药学上可接受的盐”指本发明化合物与无机和/或有机酸和碱形成的酸式和/或碱式盐，也包括两性离子盐(内盐)，还包括季铵盐，例如烷基铵盐。这些盐可以是在化合物的最后分离和纯化中直接得到。也可以是通过将上述化合物与一定数量的酸或碱适当(例如等当量)进行混合而得到。这些盐可能在溶液中形成沉淀而以过滤方法收集，或在溶剂蒸发后回收而得到，或在水介质中反应后冷冻干燥制得。本发明中所述盐可以是化合物的盐酸盐、硫酸盐、枸橼酸盐、苯磺酸盐、氢溴酸盐、氢氟酸盐、磷酸盐、乙酸盐、丙酸盐、丁二酸盐、草酸盐、苹果酸盐、琥珀酸盐、富马酸盐、马来酸盐、酒石酸盐或三氟乙酸盐。
术语“同位素标记化合物”指化合物中的一个或两个以上的原子被其对应的同位素替换后得到的化合物。比如化合物中的一个或两个以上的氢(H)被氘(D)或氚(T)替换后得到的化合物；比如化合物中的一个或两个以上的碳12被碳11或碳13替换后得到的化合物。
本发明化合物或药物组合物的施用方式没有特别限制，代表性的施用方式包括(但并不限于)：口服、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中，活性化合物与至少一种常规惰性赋形剂(或载体)混合，如柠檬酸钠或磷酸二钙，或与下述成分混合：(a)填料或增溶剂，例如，淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸；(b)粘合剂，例如，羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶；(c)保湿剂，例如，甘油；(d)崩解剂，例如，琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠；(e)缓溶剂，例如石蜡；(f)吸收加速剂，例如，季胺化合物；(g)润湿剂，例如鲸蜡醇和单硬脂酸甘油酯；(h)吸附剂，例如，高岭土；和(i)润滑剂，例如，滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠，或其混合物。胶囊剂、片剂和丸剂中，剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备，如肠衣和其它本领域公知的材料。它们可包含不透明剂，并且，这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时，活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外，液体剂型可包含本领域中常规采用的惰性稀释剂，如水或其它溶剂，增溶剂和乳化剂，例知，乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油，特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外，组合物也可包含助剂，如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外，悬浮液可包含悬浮剂，例如，乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液，和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂，或必要时可能需要的推进剂一起混合。
本发明所述药学上可接受的辅料，是指除活性成分以外包含在剂型中的物质。
本发明所述药学上可接受的辅助性成分，它具有一定生理活性，但该成分的加入不会改变上述药物组合物在疾病治疗过程中的主导地位，而仅仅发挥辅助功效，这些辅助功效仅仅是对该成分已知活性的利用，是医药领域惯用的辅助治疗方式。若将上述辅助性成分与本发明药物组合物配合使用，仍然应属于本发明保护的范围。
与现有技术相比，本发明取得了以下有益效果：
1.本发明提供的化合物是一种EZH2共价抑制剂，又称EZH2不可逆抑制剂，该化合物能够与EZH2发生共价结合，对EZH2WT和EZH2MUT均展现出低纳摩尔水平的抑制活性，对由EZH2过表达或由EZH2突变导致的疾病均具有优良的治疗潜力。
2.本发明的化合物作为一种EZH2共价抑制剂，相比与现有技术中的EZH2可逆抑制剂具有明显的优势：
(1)目前EZH2小分子可逆抑制剂大多存在给药剂量大的缺点，但是，本发明的EZH2共价抑制剂由于与EZH2蛋白形成共价键而作用较强且持久，可以减少给药剂量及给药频率。
(2)由于EZH2共价抑制剂对EZH2靶蛋白能够产生持续抑制作用，因此，它能够预防耐药性的产生。实验结果也表明，本发明提供的化合物可以有效抑制肿瘤细胞的增殖，洗脱后仍然发挥持续抑制活性，效果显著优于已上市的EZH2抑制剂EPZ6438。
(3)在异种移植瘤模型中，本发明化合物抗肿瘤活性的效果也显著优于已上市的EZH2抑制剂EPZ6438。
3.本发明化合物的合成方法原料易得，容易实现，适合工业化生成。
本领域技术人员公知的，EZH2过表达、EZH2基因突变与多种癌症(包括脑癌、成胶质细胞瘤、白血病、淋巴瘤乳腺癌、炎性乳腺癌、维尔姆斯瘤、尤因肉瘤、横纹肌肉瘤、室管膜瘤、成神经管细胞瘤、结肠癌、胃癌、膀肤癌、头颈癌、肾癌、肺癌、肝癌、黑素瘤、肾脏癌、卵巢癌、胰腺癌、前列腺癌、肉瘤、骨肉瘤、骨巨细胞瘤、甲状腺癌、宫颈癌)和自身免疫性疾病(包括银屑病或红斑狼疮)的发生发展密切相关。
本发明提供的化合物作为EZH2共价抑制剂，可以用来制备预防和治疗由EZH2过表达或由EZH2突变导致的疾病，为临床药物的开发和应用提供了新的选择。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为化合物对EZH2MUT酶活性的抑制效果。
图2为化合物与EZH2蛋白孵育后的质谱图。
图3为化合物对其他组蛋白甲基转移酶的抑制率。
图4为化合物对肿瘤细胞的增殖抑制活性(A)及洗脱后的持续抑制活性(B)。
图5为化合物对细胞内组蛋白27位赖氨酸3甲基化水平的抑制作用。
图6为化合物抑制荷瘤鼠体内肿瘤生长的效果。
具体实施方式
本发明所用原料与设备均为已知产品，通过购买市售产品所得。
实施例1 3'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A1)的制备
步骤1 5-溴-2-甲基-3-((四氢-2H-吡喃-4-基)氨基)苯甲酸甲酯的制备
将3-氨基-5-溴-2-甲基苯甲酸甲酯(5.00g,20.48mmol)、四氢吡喃酮(2.84mL,30.72mmol)和乙酸(7.30mL,125.04mmol)加入圆底烧瓶中，再加入溶剂1，2-二氯乙烷，使混合物在室温下搅拌0.5小时。然后将反应置于冰浴中并分批加入三乙酰氧基硼氢化钠(13.02g，61.44mmol)。然后在室温下反应过夜。反应完成后，用碳酸氢钠将pH调节至7-8。分离有机相，真空浓缩。粗品经硅胶柱层析纯化，得到化合物5-溴-2-甲基-3-((四氢-2H-吡喃-4-基)氨基)苯甲酸甲酯。6.12g淡黄色固体，收率：91.07％。1H NMR(400MHz,DMSO-d6)δ6.97(d,J＝1.9Hz,1H),6.93(d,J＝2.0Hz,1H),5.00(d,J＝8.0Hz,1H),3.86(dt,J＝11.6,3.7Hz,2H),3.80(s,3H),3.61–3.50(m,1H),3.44(td,J＝11.7,2.1Hz,2H),2.14(s,3H),1.83(ddd,J＝12.6,4.4,2.2Hz,2H),1.58–1.45(m,2H)。
步骤2 5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸甲酯的制备
将化合物5-溴-2-甲基-3-((四氢-2H-吡喃-4-基)氨基)苯甲酸甲酯(3.50g,10.93mmol)、乙醛(1.67mL,32.80mmol)和乙酸(3.9mL,65.58mmol)溶于1,2-二氯乙烷并在室温下搅拌0.5小时。然后在0℃分批加入三乙酰氧基硼氢化钠。然后在室温下反应过夜。反应完成后，用碳酸氢钠将pH调节至7-8。收集有机相，浓缩，柱层析，得到淡黄色固体3.08g。1H NMR(400MHz,DMSO-d6)δ7.60(d,J＝2.1Hz,1H),7.53(d,J＝2.2Hz,1H),3.85–3.79(m,5H),3.25(td,J＝11.6,2.1Hz,2H),3.04(q,J＝7.1Hz,2H),3.00–2.93(m,1H),2.36(s,3H),1.61(ddd,J＝12.7,4.4,2.1Hz,2H),1.55–1.42(m,2H),0.79(t,J＝7.0Hz,3H)。
步骤3 5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸的制备
向5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸甲酯(3.08g，8.65mmol)的乙醇溶液中加入饱和氢氧化钠水溶液(12.97mmol)，然后在60℃搅拌1小时。反应完毕后，浓缩反应液，加入适量水，用1M HCl调节pH至3-4。析出白色固体，抽滤，干燥，得到5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸。收率：93.76％。1H NMR(400MHz,DMSO-d6)δ12.99(s,1H),7.59(d,J＝2.1Hz,1H),7.49(d,J＝2.2Hz,1H),3.82(ddd,J＝11.7,4.3,2.0Hz,2H),3.04(q,J＝7.0Hz,2H),3.00–2.92(m,1H),2.38(s,3H),1.66–1.56(m,2H),1.49(qd,J＝11.7,4.4Hz,2H),0.79(t,J＝7.0Hz,3H)。
步骤4 5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺的制备
5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸(2.00g,5.84mmol),3-(氨基甲基)-4,6-二甲基吡啶-2(1H)-酮(1.16g,7.59mmol),1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐(2.02g,10.51mmol),N-羟基-7-氮杂苯并三唑(1.43g,10.51mmol)和N-甲基吗啉(3.23mL,29.20mmol)溶解在DMSO中并在25℃下反应过夜。反应完毕后，将反应液倒入冰水中，析出大量白色固体。过滤和干燥得到2.39g 5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺。它不经进一步纯化直接用于下一步反应。1H NMR(400MHz,DMSO-d6)δ11.50(s,1H),8.22(t,J＝5.0Hz,1H),7.31(d,J＝2.1Hz,1H),7.09(d,J＝2.0Hz,1H),5.86(s,1H),4.25(d,J＝5.0Hz,2H),3.86–3.78(m,2H),3.24(td,J＝11.6,2.1Hz,2H),3.01(q,J＝7.1Hz,2H),2.96–2.90(m,1H),2.19(s,3H),2.15(s,3H),2.11(s,3H),1.60(d,J＝12.2Hz,2H),1.55–1.44(m,2H),0.78(t,J＝7.0Hz,3H)。
步骤5 3'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A1)的制备
5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺(0.16g,0.34mmol),N-(3-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺(0.11g,0.41mmol)和碳酸钠(0.14g，1.36mmol)加入1,4-二氧六环和水(4:1)的混合溶剂中。将溶液用氮气吹扫3至5次，然后加入PdCl2(dppf)·CH2Cl2(0.024g，0.034mmol)。继续用氮气置换3次，然后在100℃反应4小时。反应完成后，将反应溶液在真空下浓缩。加入10％MeOH/DCM，过滤，收集滤液并浓缩。通过柱层析得到目标化合物A1，为灰白色固体。产率：56.49％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),10.24(s,1H),8.20(t,J＝5.0Hz,1H),7.85(s,1H),7.74(d,J＝8.0Hz,1H),7.45–7.31(m,3H),7.20(s,1H),6.46(dd,J＝16.8,10.2Hz,1H),6.33–6.23(m,1H),5.86(s,1H),5.83–5.71(m,1H),4.30(d,J＝4.8Hz,2H),3.88–3.79(m,2H),3.28–3.24(m,2H),3.15–2.97(m,3H),2.25(s,3H),2.21(s,3H),2.11(s,3H),1.67(d,J＝10.8Hz,2H),1.61–1.47(m,2H),0.85(t,J＝6.9Hz,3H).13C NMR(101MHz,DMSO-d6)δ169.53,163.75,163.47,150.00,149.35,140.85,140.32,140.06,137.49,133.27,132.36,129.87,127.47,125.02,123.23,122.28,122.06,121.20,118.82,117.80,107.82,66.80(2C),58.40,41.62,35.35,30.75(2C),19.42,18.66,15.04,13.24.HRMS(ESI):calcd.for C32H38N4NaO4[M+Na]+:565.2791,found:565.2794.
实施例2 3'-(丙烯酰胺甲基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A2)
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(3-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苄基)丙烯酰胺为原料，得到目标化合物A2。灰白色固体，收率：68.91％。1H NMR(400MHz,DMSO-d6)δ11.46(s,1H),8.65(t,J＝6.0Hz,1H),8.20(t,J＝5.0Hz,1H),7.50(d,J＝6.7Hz,2H),7.44–7.35(m,2H),7.28–7.18(m,2H),6.34–6.24(m,1H),6.13(dd,J＝17.1,2.4Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.42(d,J＝5.9Hz,2H),4.30(d,J＝4.9Hz,2H),3.87–3.80(m,2H),3.29–3.21(m,2H),3.09(q,J＝7.0Hz,2H),3.04–2.98(m,1H),2.24(s,3H),2.21(s,3H),2.11(s,3H),1.66(d,J＝12.3Hz,2H),1.53(m,2H),0.83(t,J＝7.0Hz,3H).13C NMR(101MHz,DMSO-d6)δ169.46,165.13,149.35,140.46,140.38,140.31,137.65,133.18,132.26,132.15,129.50,129.43,126.88,126.11,125.83,125.63,123.41,121.26,115.30,114.88,107.83,66.80(2C),58.36,49.07,42.66,41.67,35.68,30.78(2C),19.37,15.01,13.18.HRMS(ESI):calcd.forC33H40N4NaO4[M+Na]+:579.2947,found:579.2944.
实施例3 4'-(丙烯酰胺甲基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A3)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苄基)丙烯酰胺为原料，得到目标化合物A3。灰白色固体，收率：59.88％。1HNMR(400MHz,DMSO-d6)δ11.45(s,1H),8.62(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.37(d,J＝5.8Hz,2H),4.29(d,J＝4.8Hz,2H),3.88–3.78(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.04–2.96(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.70–1.61(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).13CNMR(101MHz,DMSO-d6)δ169.54,165.07,163.49,149.98,149.35,143.22,140.15,138.94,137.45,133.08,132.14,128.48(2C),127.04(2C),125.86,123.39,122.08,121.23,115.52,107.84,66.80(2C),58.32,42.39,41.66,35.39,30.78(2C),19.42,18.66,15.01,13.18.HRMS(ESI):calcd.for C33H41N4O4[M+H]+:557.3128,found:557.3132.
实施例4 5'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-2',4-二甲基-[1,1'-联苯]-3-甲酰胺(化合物A4)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(4-甲基-3-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)丙烯酰胺为原料，得到目标化合物A4。灰白色固体，收率：57.74％。1H NMR(400MHz,DMSO-d6)δ11.39(s,1H),10.14(s,1H),8.16(t,J＝5.0Hz,1H),7.63–7.56(m,1H),7.50(d,J＝2.3Hz,1H),7.22(d,J＝8.3Hz,1H),7.11(s,1H),6.89(s,1H),6.43(dd,J＝16.9,10.1Hz,1H),6.23(dd,J＝17.0,2.1Hz,1H),5.85(s,1H),5.79–5.66(m,1H),4.28(d,J＝4.8Hz,2H),3.83(d,J＝10.9Hz,2H),3.40–5.66(m,2H),3.09–2.98(m,3H),2.26(s,3H),2.19(s,3H),2.17(s,3H),2.10(s,3H),1.65(d,J＝12.2Hz,2H),1.53(tt,J＝12.3,6.2Hz,2H),0.84(t,J＝6.9Hz,3H).13C NMR(101MHz,DMSO-d6)δ169.51,163.52,163.50,149.92,148.41,143.25,141.48,139.74,138.45,137.40,132.47,132.40,131.14,130.28,127.12,125.80,123.19,122.03,120.80,118.83,107.82,66.75(2C),58.16,41.61,35.38,30.75(2C),20.10,19.39,18.66,15.00,13.02.HRMS(ESI):calcd.forC33H40N4NaO4[M+Na]+:579.2947,found:579.2947.
实施例5 4'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A5)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A5。灰白色固体，收率49.1％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),8.62(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.29(d,J＝4.8Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C32H38N4NaO4[M+Na]+:565.2791,found:565.2793.
实施例6 4'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-2',4-二甲基-[1,1'-联苯]-3-甲酰胺(化合物A6)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(3-甲基-4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯基)丙烯酰胺为原料，得到目标化合物A6。白色固体，收率37.92％。1H NMR(400MHz,DMSO-d6)δ11.39(s,1H),10.14(s,1H),8.16(t,J＝5.0Hz,1H),7.90–7.84(m,1H),7.80(d,J＝2.3Hz,1H),7.72(d,J＝8.3Hz,1H),7.01(s,1H),6.89(s,1H),6.43(dd,J＝16.9,10.1Hz,1H),6.23(dd,J＝17.0,2.1Hz,1H),5.85(s,1H),5.79–5.66(m,1H),4.28(d,J＝4.8Hz,2H),3.83(d,J＝10.9Hz,2H),3.40–5.66(m,2H),3.09–2.98(m,3H),2.26(s,3H),2.19(s,3H),2.17(s,3H),2.10(s,3H),1.65(d,J＝12.2Hz,2H),1.53(tt,J＝12.3,6.2Hz,2H),0.84(t,J＝6.9Hz,3H)。HRMS(ESI):calcd.for C33H40N4NaO4[M+Na]+:579.2947,found:579.2946。
实施例7 4'-(2-丙烯酰胺乙基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基))氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A7)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苯乙基)丙烯酰胺为原料，得到目标化合物A7。灰白色固体，收率46.31％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),8.62(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.37(d,J＝5.8Hz,2H),4.29(d,J＝4.8Hz,2H),3.78–3.68(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.04–2.93(m,3H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.70–1.61(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C34H43N4O4[M+H]+:571.3284,found:571.3280.
实施例8 5-(1-丙烯酰基-1,2,3,6-四氢吡啶-4-基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺(化合物A8)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、1-(4-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)-3,6-二氢吡啶-1(2H)-基)丙-2-烯-1-酮为原料，得到目标化合物A8。淡黄色固体，收率24.89％。1H NMR(400MHz,DMSO-d6)δ11.50(s,1H),8.22(t,J＝5.0Hz,1H),7.31(d,J＝2.1Hz,1H),7.09(d,J＝2.0Hz,1H),6.76(ddd,J＝37.5,16.7,10.5Hz,1H),6.55(d,J＝21.6Hz,1H),6.08(dd,J＝15.9,3.2Hz,1H),5.86(s,1H),5.66(dd,J＝10.5,2.4Hz,1H),4.25(d,J＝5.0Hz,2H),4.06–3.96(m,2H),3.86–3.78(m,2H),3.65–3.47(m,2H),3.24(td,J＝11.6,2.1Hz,2H),3.01(q,J＝7.1Hz,2H),2.96–2.90(m,1H),2.19(s,3H),2.18(d,J＝21.5Hz,2H),2.15(s,3H),2.11(s,3H),1.60(d,J＝12.2Hz,2H),1.55–1.44(m,2H),0.78(t,J＝7.0Hz,3H)。HRMS(ESI):calcd.for C31H41N4O4[M+H]+:533.3128,found:533.3131.
实施例9 5-(1-丙烯酰基-2,5-二氢-1H-吡咯-3-基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺(化合物A9)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、1-(3-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)-2,5-二氢-1H-吡咯-1-基)丙-2-烯-1-酮为原料，得到目标化合物A9。淡黄色固体，收率19.82％。1H NMR(400MHz,DMSO-d6)δ11.50(s,1H),8.22(t,J＝5.0Hz,1H),7.31(d,J＝2.1Hz,1H),7.09(d,J＝2.0Hz,1H),6.57(ddd,J＝24.3,16.8,10.3Hz,1H),6.47(dq,J＝8.5,2.1Hz,1H),6.14(ddd,J＝16.8,5.4,2.4Hz,1H),5.86(s,1H),5.67(ddd,J＝10.5,8.8,2.4Hz,1H),4.45–4.35(m,2H),4.25(d,J＝5.0Hz,2H),4.23–4.14(m,2H),3.86–3.78(m,2H),3.24(td,J＝11.6,2.1Hz,2H),3.01(q,J＝7.1Hz,2H),2.96–2.90(m,1H),2.19(s,3H),2.15(s,3H),2.11(s,3H),1.60(d,J＝12.2Hz,2H),1.55–1.44(m,2H),0.78(t,J＝7.0Hz,3H)。HRMS(ESI):calcd.forC30H39N4O4[M+H]+:519.2971,found:519.2969.
实施例10 4'-丙烯酰胺基-5-(乙基(四氢-2H-吡喃-4-基)氨基)-N-((4-乙基-6-甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A10)的制备
参照实施例1的制备方法，以5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸、3-(氨基甲基)-4-乙基-6-甲基吡啶-2(1H)-酮、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A10。灰白色固体，收率45.21％。1HNMR(400MHz,DMSO-d6)δ11.56(s,1H),8.62(t,J＝6.1Hz,1H),7.69(t,J＝5.5Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.92(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.49(d,J＝5.2Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.63(q,J＝7.3Hz,2H),2.13(s,3H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H),1.11(t,J＝7.6Hz,3H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C33H40N4NaO4[M+Na]+:579.2947,found:579.2944.
实施例11 4'-丙烯酰胺基-N-((4,6-二乙基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A11)的制备
参照实施例1的制备方法，以5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸、3-(氨基甲基)-4,6-二乙基吡啶-2(1H)-酮、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A11。灰白色固体，收率52.11％。1HNMR(400MHz,DMSO-d6)δ11.55(s,1H),8.62(t,J＝6.1Hz,1H),7.69(t,J＝7.9Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.94(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.49(d,J＝5.5Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.64(q,J＝7.7Hz,2H),2.43(q,J＝7.7Hz,2H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H),1.12(t,J＝6.8,6.1Hz,6H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.forC34H42N4NaO4[M+Na]+:593.3104,found:593.3108.
实施例12 4'-(丙烯酰胺甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-N-((1-甲基-3-氧代-2,3,5,6,7,8-六氢异喹啉-4-基)甲基)-[1,1'-联苯]-3-甲酰胺(化合物A12)的制备
参照实施例1的制备方法，以5-溴-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酸、4-(氨基甲基)-1-甲基-5,6,7,8-四氢异喹啉-3(2H)-酮、N-(4,4,5,5-四甲基-1,3,2-二氧苯甲醛-2-基)苄基)丙烯酰胺为原料，得到目标化合物A12。灰白色固体，收率：56.22％。1H NMR(400MHz,DMSO-d6)δ11.49(s,1H),8.62(t,J＝6.0Hz,1H),8.16(t,J＝4.9Hz,1H),7.58(d,J＝7.9Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝8.0Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.37(d,J＝5.8Hz,2H),4.31(d,J＝4.8Hz,2H),3.83(d,J＝11.6Hz,2H),3.25(t,J＝11.4Hz,2H),3.08(q,J＝7.0Hz,2H),3.04–2.97(m,1H),2.74(d,J＝6.2Hz,2H),2.38(d,J＝5.7Hz,2H),2.24(s,3H),2.10(s,3H),1.70–1.60(m,6H),1.59–1.47(m,2H),0.83(t,J＝6.9Hz,3H).13C NMR(101MHz,DMSO-d6)δ169.56,165.06,162.04,150.53,149.36,140.17,138.99,138.94,137.44,133.07,132.13,129.24,128.48(2C),127.03(2C),125.86,123.40,121.22,115.51,112.04,66.80(2C),58.30,42.39,41.68,35.13,30.79(2C),27.11,24.59,22.65,22.40,16.43,15.02,13.16.HRMS(ESI):calcd.forC36H44N4NaO4[M+Na]+:619.3260,found:619.3257。
实施例13 (E)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3'-(4-(二甲氨基)但-2-烯酰胺)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-[1,1'-联苯基]-3-甲酰胺(化合物A13)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、(E)-4-(二甲基氨基)-N-(3-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丁-2-烯酰胺为原料，得到目标化合物A13。灰白色固体，收率10.34％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),9.05(s,1H),8.20(t,J＝5.0Hz,1H),7.74(d,J＝8.0Hz,1H),7.45–7.31(m,4H),7.20(s,1H),6.70(dt,J＝14.7,7.1Hz,1H),6.35(d,J＝15.4Hz,1H),5.86(s,1H),4.43(d,J＝5.9Hz,2H),4.30(d,J＝4.8Hz,2H),3.88–3.79(m,2H),3.28–3.24(m,2H),3.15–2.97(m,3H),2.73(s,6H),2.25(s,3H),2.21(s,3H),2.11(s,3H),1.67(d,J＝10.8Hz,2H),1.61–1.47(m,2H),0.85(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C35H45N5NaO4[M+Na]+:622.3369,found:622.3371.
实施例14 4'-(2-氯乙酰胺基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基))氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物14)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、2-氯-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)乙酰胺为原料，得到目标化合物A14。黄色固体，收率12.73％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),8.62(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),5.86(s,1H),4.32(s,2H),4.29(d,J＝4.8Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C31H37ClN4NaO4[M+Na]+:587.2401,found:587.2400.
实施例15 4'-(2,2-二氯乙酰胺)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4)-基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A15)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、2,2-二氯-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)乙酰胺为原料，得到目标化合物A15。黄色固体，收率11.91％。1H NMR(400MHz,DMSO-d6)δ11.39(s,1H),8.52(t,J＝6.1Hz,1H),8.10(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.36(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),5.86(s,1H),5.45(s,1H),4.29(d,J＝4.8Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C31H36Cl2N4NaO4[M+Na]+:621.2011,found:621.2007.
实施例16 4'-(3-氯丙酰胺基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基))氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A16)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、3-氯-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙酰胺为原料，得到目标化合物A16。黄色固体，收率9.76％。1H NMR(400MHz,DMSO-d6)δ11.40(s,1H),8.91(t,J＝6.1Hz,1H),8.32(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),5.86(s,1H),4.29(d,J＝4.8Hz,2H),3.89–3.80(m,4H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.05–2.94(m,1H),2.83(t,J＝3.1Hz,2H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.70–1.59(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C32H39ClN4NaO4[M+Na]+:601.2558,found:601.2555.
实施例17 4'-((氯甲基)磺酰胺基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-)基)氨基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A17)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、1-氯-N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)甲磺酰胺为原料，得到目标化合物A17。黄色固体，收率14.21％。1H NMR(400MHz,DMSO-d6)δ11.38(s,1H),8.67(t,J＝6.1Hz,1H),8.21(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.35(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),5.86(s,1H),5.52(s,2H),4.29(d,J＝4.8Hz,2H),3.89–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.01–2.93(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.69–1.61(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.for C30H37ClN4NaO5S[M+Na]+:623.2071,found:623.2070.
实施例18 N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-5-(乙基(四氢-2H-吡喃-4-基)氨基)-4-甲基-4'-(乙烯基磺酰胺)-[1,1'-联苯]-3-甲酰胺(化合物A18)的制备
参照实施例1的制备方法，以5-溴-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-3-(乙基(四氢-2H-吡喃-4-基)氨基)-2-甲基苯甲酰胺、N-(4,4,5,5-四甲基-1,3,2-二氧苯并呋喃-2-基)苯基)乙烯磺酰胺为原料，得到目标化合物A18。黄色固体，收率10.54％。1H NMR(400MHz,DMSO-d6)δ11.48(s,1H),8.77(t,J＝6.1Hz,1H),8.23(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.34–6.24(m,1H),6.13(dd,J＝17.1,2.4Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.30(d,J＝4.8Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),3.08(q,J＝7.2Hz,2H),3.03–2.93(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.68–1.61(m,2H),1.52(td,J＝11.5,7.7Hz,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.forC31H38N4NaO5S[M+Na]+:601.2461,found:601.2465.
实施例19 4'-丙烯酰胺基-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-4-甲基-5-(甲基(四氢-2H-吡喃-4-基))氨基)-[1,1'-联苯]-3-甲酰胺(化合物A19)的制备
参照实施例1的制备方法，以5-溴-2-甲基-3-((四氢-2H-吡喃-4-基)氨基)苯甲酸甲酯、甲醛、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A19。灰白色固体，收率50.32％。1H NMR(400MHz,DMSO-d6)δ11.45(s,1H),8.62(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.29(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.29(d,J＝4.8Hz,2H),3.90–3.81(m,2H),3.25(t,J＝11.6Hz,2H),2.70(s,3H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.71–1.60(m,2H),1.52(td,J＝11.5,7.7Hz,2H).HRMS(ESI):calcd.forC31H36N4NaO4[M+Na]+:551.2634,found:551.2630.
实施例20 4'-丙烯酰胺-5-(环戊基(乙基)氨基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A20)的制备
参照实施例1的制备方法，以3-氨基-5-溴-2-甲基苯甲酸甲酯、环戊酮、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A20。灰白色固体，收率44.32％。1H NMR(400MHz,DMSO-d6)δ11.41(s,1H),8.57(t,J＝6.1Hz,1H),8.16(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.36(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.25(dd,J＝17.1,10.1Hz,1H),6.11(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.53(dd,J＝10.1,2.3Hz,1H),4.82–4.71(m,1H),4.29(d,J＝4.8Hz,2H),3.08(q,J＝7.2Hz,2H),2.24(s,3H),2.21(s,3H),2.18-2.11(m,2H),2.10(s,3H),2.07–2.01(m,2H),1.88–1.79(m,2H),1.74–1.61(m,2H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.forC32H38N4NaO3[M+Na]+:549.2842,found:549.2845.
实施例21 4'-丙烯酰胺基-5-(环己基(乙基)氨基)-N-((4,6-二甲基-2-氧代-1,2-二氢吡啶-3-基)甲基)-4-甲基-[1,1'-联苯]-3-甲酰胺(化合物A21)的制备
参照实施例1的制备方法，以3-氨基-5-溴-2-甲基苯甲酸甲酯、环己酮、N-(4-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)苯基)丙烯酰胺为原料，得到目标化合物A21。灰白色固体，收率59.31％。1H NMR(400MHz,DMSO-d6)δ11.43(s,1H),8.61(t,J＝6.1Hz,1H),8.19(t,J＝5.0Hz,1H),7.58(d,J＝8.0Hz,2H),7.38(d,J＝1.9Hz,1H),7.34(d,J＝7.9Hz,2H),7.21(d,J＝1.8Hz,1H),6.27(dd,J＝17.1,10.1Hz,1H),6.13(dd,J＝17.1,2.3Hz,1H),5.86(s,1H),5.63(dd,J＝10.1,2.3Hz,1H),4.29(d,J＝4.8Hz,2H),3.08(q,J＝7.2Hz,2H),3.02–2.94(m,1H),2.24(s,3H),2.21(s,3H),2.10(s,3H),1.71–1.60(m,4H),1.52(td,J＝11.5,7.7Hz,2H),1.41–1.30(m,4H),0.83(t,J＝6.9Hz,3H).HRMS(ESI):calcd.forC33H40N4NaO3[M+Na]+:563.2998,found:563.2993.
以下通过试验例证明本发明的有益效果。
试验例1本发明化合物抑制EZH2WT及EZH2MUT体外酶活性
1.实验方法
化合物抑制EZH2WT和EZH2MUT酶活性实验：采用AlphaLISA筛选方法对化合物进行EZH2WT和EZH2MUT酶活性测试。方法如下：分别取100μL不同浓度的化合物溶液加入到384孔检测板中，采用三倍稀释法，最高浓度为1000nM，最低浓度为1nM，每个药物浓度设置2个复孔。然后分别在各孔中加入5μL的EZH2WT酶或EZH2MUT酶溶液，1000rpm/min离心1min后孵育15min。再加入5μL底物(SAM：S-腺苷甲硫氨酸)，1000rpm/min分离心1min，室温孵育1h。孵育结束后加入5μL受体磁珠来终止酶反应，同样1000rpm/min离心1min，室温孵育1h，最后再避光条件下加入10μL供体磁珠，1000rpm/min离心1min，室温孵育30min，采用EnSpire的Alpha模式检测信号强度。计算化合物对EZH2WT或EZH2MUT活性的半数抑制浓度(IC50)。以已上市的EZH2抑制剂EPZ6438作为对照。
EZH2WT表示野生型EZH2，EZH2MUT表示突变型EZH2。本试验中的EZH2MUT包括EZH2A677G、EZH2Y641N和EZH2Y641F。
2.实验结果
本发明化合物抑制EZH2WT体外酶活性结果见下表1，其中，字母A表示IC50值≤5nM；字母B表示5nM<IC50值≤10nM；字母C表示10nM<IC50值≤50nM；字母D表示50nM<IC50值≤100nM；字母E表示100nM<IC50值≤1000nM。
表1本发明化合物对EZH2WT体外酶活性的抑制效果
从表1中可以看出，本发明中多数化合物在微摩尔浓度下能够有效抑制EZH2WT体外酶活性，其中A1-A4、A7、A14、A15的半数抑制浓度低于5nM，说明本发明化合物对EZH2具有强烈的抑制活性。
已有研究表明，EZH2的突变(包括SET结构域中的A677G、Y641N/F/S/H/C和Y687V)已在多种癌症中检测到，并且与肿瘤的发生发展密切相关。图1为本发明化合物A4和已上市的EZH2抑制剂EPZ6438对EZH2MUT的抑制活性测试结果。可以看出，10nM的A4对EZH2A677G、EZH2Y641N和EZH2Y641F均显示出良好的抑制活性，与上市药物EPZ6438产生的活性相当。另外，即使在1nM的浓度下，A4仍对EZH2A677G保持较高抑制作用。这些结果表明A4可有效抑制EZH2的A677G、Y641N和Y641F突变体，对由EZH2突变驱动的癌症具有治疗潜力。
上述实验结果表明，本发明提供的化合物对EZH2WT和EZH2MUT均展现出低纳摩尔水平的抑制活性，对由EZH2过表达或由EZH2突变导致的癌症均具有治疗潜力。
试验例2本发明化合物的共价作用机制验证
1.实验方法
实验原理：蛋白质和共价抑制剂孵育后进行质谱实验，若相对于纯蛋白质谱，加合物的质谱发生偏移，且增加质量刚好为抑制剂的分子量，可确证抑制剂与EZH2蛋白发生共价连接。
测试方法：
a.EZH2(SET)蛋白表达纯化
本实验中采用全基因合成的方式构建质粒并亚克隆到pET-28a表达载体上，进一步转化到大肠杆菌感受态细胞、培养、诱导表达、收集菌体、纯化蛋白，最后通过SDS-PAGE以及WB验证获得纯度>90％重组EZH2蛋白。具体操作方法如下：
(1)质粒构建及验证：a)根据EZH2氨基酸序列AA494-737设计引物，通过PCR扩增出足够量的PCR产物；b)通过连接酶将PCR产物和克隆载体进行连接；c)对克隆载体进行酶切，将外源基因酶连至终载；d)连接液转入TOP10感受态中，检测筛选出阳性克隆进行测序验证。
(2)蛋白表达：a)将重组质粒转入Rosetta(DE3)大肠杆菌感受态细胞，42℃热激后涂布在含有30μg/mL卡那霉素和34μg/mL氯霉素的平板上，37℃培养；b)挑取单克隆菌落到含有30μg/mL卡那霉素和34μg/mL氯霉素的液体培养基中37℃培养；c)当OD值达到0.6时，添加0.5mM诱导剂IPTG，继续培养，分别于20℃条件下培养过夜，37℃条件下培养6h，未添加诱导剂的为阴性对照；d)4000rpm离心10min，弃上清，收集菌体；e)在收集到的菌体中加入缓冲液(1XPBS,pH 7.4)悬浮，使用超声破碎仪使其充分溶解。离心收集上清和沉淀，沉淀使用缓冲液(8M Urea,50mM Tris-HCl,300mM NaCl,pH8.0)进行溶解，分别对上清和沉淀蛋白进行制样，准备上胶检测；f)在含30μg/mL卡那霉素和34μg/mL氯霉素的培养基中培养菌液，当OD值达到0.6时，添加0.5mM诱导剂IPTG，20℃条件下培养过夜进行大量表达，离心收集细胞菌体。
(3)蛋白纯化：a)细胞菌体用缓冲液(8M Urea,50mM Tris,300mM NaCl,0.1％Triton X-100,0.2％Triton X-114,pH 8.0)溶解、超声破碎，离心收集上清粗蛋白；b)取5mL Ni-NTA，用10倍柱床体积的Binding buffer清洗平衡柱子；c)将粗蛋白与平衡后的柱填料孵育1h，收集流出；d)用缓冲液(8MUrea,50mM Tris,300mM NaCl,0.2％Triton X-114,pH 8.0)清洗平衡柱子；e)用Washing buffer洗柱子，并收集流出；f)用Elution buffer洗脱，收集流出；g)对粗蛋白、流出组分分别处理，制样，准备SDS-PAGE检测；h)将纯化后的组分5透析到蛋白保存缓冲液1XPBS，0.1％SKL，2mM DTT，pH 7.4中，透析结束后用PEG20000浓缩，0.45μm滤膜过滤后分装1mL/tube，-80℃保存。
(4)蛋白纯度检测：a)对蛋白样品进行处理，制样，12％分离胶，5％浓缩胶，跑胶，检测分子量；b)对蛋白样品进行处理，制样，浓缩胶5％，分离胶12％，一抗为鼠抗His标签，二抗为羊抗鼠，采用TMB显色，使用标签抗体进行验证。
b.蛋白质谱实验
本实验中采用LC-MS进行蛋白质谱分析，由生工生物工程(上海)股份有限公司提供测试服务。操作简述如下：
(1)纯EZH2蛋白或化合物-蛋白复合物(37℃孵育15分钟)经处理失活后取适量供试品于进样瓶中。
(2)样品采用超高效液相色谱系统进行分离。流动相A：0.1％甲酸水溶液；流动相B：0.1％甲酸乙腈溶液。流动相以起始梯度平衡系统至达到基线平衡，质谱校正完成后按照空白、供试品的顺序进样，具体液相色谱条件见下表2。
表2超高效液相色谱条件
(3)数据分析：使用UNIFI软件对原始数据进行去卷积分析，获得精确分子量数值。
2.实验结果
如图2所示，化合物A4与EZH2(SET)蛋白孵育后，质谱上出现了分子量为29710.50的峰，相对于EZH2(SET)蛋白的质谱增量刚好为A4的分子量(MW：556.71)，误差为35.0ppm，在误差范围内(≤50ppm)。
上述实验结果表明化合物A4和EZH2蛋白发生了有效的共价结合。
试验例3本发明化合物抑制作用的选择性
1.实验方法
目前已有超过60个组蛋白甲基转移酶被报道，对组蛋白多个位点的赖氨酸和精氨酸进行甲基化修饰，发挥着重要的生理学作用。本实验选取常见的几种组蛋白甲基转移酶考察A4的选择性，实验方法参照试验例1。
2.实验结果
如图3所示，10μM A4对G9a、SUV39H1、SETD8等7种组蛋白甲基转移酶的抑制率均未超过20％，结合试验例1的实验结果，可以看出本发明化合物具有优异的甲基转移酶选择性。
试验例4本发明化合物对肿瘤细胞的增殖抑制活性及洗脱后的持续抑制活性
1.实验方法
(1)抗肿瘤活性：分别将卵巢癌细胞A2780、PA-1与化合物A4共培养3天和5天，测试化合物A4的抗肿瘤活性。
(2)洗脱后的抗肿瘤活性：在化合物处理PA-1细胞3天后，充分洗脱化合物后，用不含药的新鲜培养基继续培养细胞1-4天，并测试化合物的抗肿瘤活性。
以化合物A4的可逆类似物A4’和已上市的EZH2抑制剂EPZ6438作为对照。
2.实验结果
如图4A所示，A4可在作用3天和5天后显著抑制两种卵巢癌细胞的增殖，且抑制活性优于已上市的EZH2抑制剂EPZ6438。
如图4B所示，A4可持续抑制PA-1细胞的增殖，活性显著优于EPZ6438和可逆类似物A4’。
上述实验结果表明，本发明化合物对卵巢癌细胞的增殖抑制活性优于已上市的EZH2抑制剂EPZ6438。
试验例5本发明化合物对细胞内组蛋白27位赖氨酸3甲基化水平的抑制作用
1.实验方法
EZH2蛋白是PRC2的核心组成部分，起组蛋白甲基转移酶的作用，能使H3K27侧链上的ε氨基发生三甲基化。H3K27三甲基化被认为是在PcG沉默机制中起作用的主要存在形式。三甲化后的H3K27后能将PRC1复合物招募到特定基因位点，从而沉默与细胞分化、抑制增殖在内的基因，导致肿瘤的发生。本发明考察了化合物A4对卵巢癌细胞A278、PA-1内的H3K27me3的表达水平的影响。
用10μM化合物A4处理癌细胞1天、2天、3天、4天，检测化合物不同作用时间对全细胞萃取物的H3K27me3水平的影响。同时考察不同浓度的化合物处理细胞3天后，全细胞萃取物的H3K27me3表达情况。
2.实验结果
从图5A可以看出，从第2天开始，细胞内的H3K27me3的表达受到显著抑制，并随着作用时间的增长抑制作用越来越明显作用。
图5B结果显示，浓度为1.2μM开始可以明显抑制H3K27me3的表达，并呈现浓度依赖性。
上述实验结果表明，本发明化合物能够显著抑制卵巢癌细胞内H3K27me3的表达。
试验例6本发明化合物对于荷瘤鼠体内肿瘤的生长抑制作用
1.实验方法
本实验为了评价化合物A4的体内治疗效果，将PA-1癌细胞通过皮下移植至裸鼠建立异种移植瘤模型。同时，以已上市的EZH2抑制剂EPZ6438作为阳性对照。给药剂量：EPZ6438口服150mg/kg、A4口服75mg/kg或150mg/kg，每天2次，为期4周。
2.实验结果
如图6所示，A4可显著抑制荷瘤鼠体内肿瘤的生长，且在同等剂量下，A4的抗肿瘤活性优于已上市的EZH2抑制剂EPZ6438。
上述实验结果表明，与已上市的EZH2抑制剂EPZ6438相比，本发明化合物在体内抑制肿瘤生长的效果显著提高。
综上，本发明提供的式I所示化合物能够与EZH2发生共价结合，对EZH2WT和EZH2MUT均展现出低纳摩尔水平的抑制活性，对由EZH2过表达或由EZH2突变导致的疾病均具有优良的治疗潜力；该化合物可有效抑制肿瘤细胞的增殖，洗脱后仍然发挥持续抑制活性，能够预防耐药性的产生，效果显著优于已上市的EZH2抑制剂EPZ6438；该化合物在异种移植瘤模型中的抗肿瘤活性的效果也显著优于已上市的EZH2抑制剂EPZ6438。本发明提供的化合物作为EZH2共价抑制剂，可以用来制备预防和治疗由EZH2过表达或由EZH2突变导致的疾病，为临床药物的开发和应用提供了新的选择。
Claims (15)
1.式Ⅰ所示的化合物物或其药学上可接受的盐：
其中，R1、R2、R3各自独立地选自H、C1-6烷基；或者，R1选自H、C1-6烷基，R2、R3连接形成5～8元饱和环烷基；
R4选自H、C1-6烷基；
R5选自未被取代或被取代基取代的以下基团：3～8元饱和环烷基、3～8元饱和杂环基；所述饱和杂环基中的杂原子选自N、O或S，杂原子个数为1～3个；所述取代基选自C1-6烷基；
L选自m选自0，1，2，3；n选自0，1，2，3；R8各自独立地选自氢、C1-6烷基；p选自0，1，2，3；
R6为X选自CO、SO2；R9选自卤素；R10、R11各自独立地选自H、卤素；Y选自CO、SO2；
R7选自H、C1-6烷基。
2.根据权利要求1所述的化合物或其药学上可接受的盐，其特征在于：所述化合物的结构如式II所示：
其中，R1、R2、R3各自独立地选自H、C1-3烷基；或者，R1选自H、C1-3烷基，R2、R3连接形成5～6元饱和环烷基；
R4选自H、C1-3烷基；
R7选自H、C1-3烷基；
n选自0，1，2，3；
R8选自氢、C1-3烷基；
X选自CO、SO2；
R9选自卤素；
R10、R11各自独立地选自H、卤素。
3.根据权利要求1所述的化合物或其药学上可接受的盐，其特征在于：所述化合物的结构如式III所示：
其中，R1、R2、R3各自独立地选自H、C1-3烷基；或者，R1选自H、C1-3烷基，R2、R3连接形成5～6元饱和环烷基；
R4选自H、C1-3烷基；
R7选自H、C1-3烷基；
n选自0，1，2，3；
R8选自氢、C1-3烷基；
Y选自CO、SO2。
4.根据权利要求1所述的化合物或其药学上可接受的盐，其特征在于：R1、R2、R3各自独立地选自H、C1-2烷基；或者R1选自H、C1-2烷基，R2、R3连接形成6元饱和环烷基；
和/或，R4选自H、C1-2烷基；
和/或，R5选自未被取代或被取代基取代的以下基团：5～6元饱和环烷基、5～6元饱和杂环基；所述取代基选自C1-6烷基；
和/或，L选自
和/或，R6选自
和/或，R7选自H、C1-2烷基。
5.根据权利要求1所述的化合物或其药学上可接受的盐，其特征在于：所述化合物选自如下结构：
6.权利要求1-5任一项所述的化合物的制备方法，其特征在于：所述制备方法包括以下步骤：
步骤1：化合物A与化合物B在还原剂的作用下进行还原胺化反应，得到化合物C；
步骤2：化合物C与化合物D在还原剂的作用下进行还原胺化反应，得到化合物E；
步骤3：化合物E进行水解反应，得到化合物F；
步骤4：化合物F与化合物G在偶联剂的作用下反应，得到化合物H；
步骤5：化合物H和化合物J在钯催化剂的作用下反应，得到式I所示化合物；
其中，R1-R7、L如权利要求1-5任一项所述。
7.根据权利要求6所示的制备方法，其特征在于：步骤1中，所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠、硼氢化钠中的任意一种或两种以上的混合物；所述反应的溶剂为二氯乙烷、三氯甲烷、二氯甲烷中的任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤2中，所述还原剂选自三乙酰氧基硼氢化钠、氰基硼氢化钠、硼氢化钠中的任意一种或两种以上的混合物；所述反应的溶剂为二氯乙烷、三氯甲烷、二氯甲烷中的任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤3中，所述水解反应是在碱溶液中进行的；所述碱为碳酸钠、氢氧化钠、氢氧化钾中任意一种或两种以上的混合物；所用碱溶液中的溶剂为醇类溶剂、水中的任意一种或两种的混合物；所述水解反应的温度为40～90℃；
步骤4中，所述偶联剂选自1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐、N-羟基-7-氮杂苯并三氮唑、1-羟基苯并三唑中任意一种或两种以上的混合物；所述反应的溶剂为二甲亚砜、N，N-二甲基甲酰胺、四氢呋喃、二氯甲烷中任意一种或两种以上的混合物；所述反应的温度为15～30℃；
步骤5中，所述钯催化剂选自([1,1'-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物、醋酸钯或四(三苯基磷)钯)中任意一种或两种的混合物；所述反应的溶剂为二氧六环和水的混合溶液；所述反应的温度为90～110℃。
8.一种药物组合物，其特征在于：它是以权利要求1-5任一项所述的化合物或其药学上可接受的盐为活性成分，加入药学上可接受的辅料或者辅助性成分制备而成的制剂。
9.权利要求1-5任一项所述的化合物或其药学上可接受的盐在制备EZH2抑制剂中的用途。
10.根据权利要求9所述的用途，其特征在于：所述EZH2抑制剂为EZH2共价抑制剂。
11.根据权利要求9所述的用途，其特征在于：所述EZH2抑制剂为抑制野生型EZH2和/或突变型EZH2的药物。
12.根据权利要求11所述的用途，其特征在于：所述突变型EZH2包括A677G、A687V、Y641N、Y641F、Y641S、Y641H。
13.根据权利要求9-12任一项所述的用途，其特征在于：所述EZH2抑制剂为预防和/或治疗癌症或自身免疫性疾病的药物。
14.根据权利要求13所述的用途，其特征在于：所述癌症包括脑癌、白血病、淋巴瘤、乳腺癌、维尔姆斯瘤、尤因肉瘤、横纹肌肉瘤、室管膜瘤、成神经管细胞瘤、结肠癌、胃癌、膀肤癌、头颈癌、肾癌、肺癌、肝癌、黑素瘤、卵巢癌、胰腺癌、前列腺癌、肉瘤、骨巨细胞瘤、甲状腺癌、宫颈癌；所述自身免疫性疾病包括银屑病或红斑狼疮。
15.根据权利要求14所述的用途，其特征在于：所述乳腺癌为炎性乳腺癌，所述脑癌为成胶质细胞瘤，所述肉瘤为骨肉瘤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210832077.XA CN115197202B (zh) | 2022-07-15 | 2022-07-15 | 一种ezh2共价抑制剂及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210832077.XA CN115197202B (zh) | 2022-07-15 | 2022-07-15 | 一种ezh2共价抑制剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115197202A CN115197202A (zh) | 2022-10-18 |
| CN115197202B true CN115197202B (zh) | 2024-01-26 |
Family
ID=83582376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210832077.XA Active CN115197202B (zh) | 2022-07-15 | 2022-07-15 | 一种ezh2共价抑制剂及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115197202B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104080769A (zh) * | 2011-04-13 | 2014-10-01 | Epizyme股份有限公司 | 芳基或杂芳基取代苯化合物 |
| CN109069508A (zh) * | 2016-04-22 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | Ezh2抑制剂及其用途 |
| WO2020192650A1 (zh) * | 2019-03-25 | 2020-10-01 | 上海华汇拓医药科技有限公司 | 酰胺类化合物制备方法及其在医药领域的应用 |
-
2022
- 2022-07-15 CN CN202210832077.XA patent/CN115197202B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104080769A (zh) * | 2011-04-13 | 2014-10-01 | Epizyme股份有限公司 | 芳基或杂芳基取代苯化合物 |
| CN109069508A (zh) * | 2016-04-22 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | Ezh2抑制剂及其用途 |
| WO2020192650A1 (zh) * | 2019-03-25 | 2020-10-01 | 上海华汇拓医药科技有限公司 | 酰胺类化合物制备方法及其在医药领域的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115197202A (zh) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021185233A1 (en) | Kras mutant protein inhibitors | |
| USRE47428E1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| KR100816945B1 (ko) | 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염 | |
| KR20220119088A (ko) | Kras 돌연변이체 단백질 억제제 | |
| CN111362967B (zh) | 苯并氧杂二氮杂十四碳烯衍生物及其用途 | |
| CN109952300A (zh) | 作为吲哚胺2,3-二加氧酶和/或色氨酸2,3-二加氧酶选择性抑制剂的新颖的5或8-取代的咪唑并[1,5-a]吡啶 | |
| AU7697594A (en) | Further pyrimidine derivatives and their preparation | |
| OA12735A (en) | Salts forms of E-2-methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-YL)-allyl)-acetamide, its preparation ant its use against cancer. | |
| CN112566900A (zh) | 免疫调节剂及其组合物和制备方法 | |
| WO2014135028A1 (zh) | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 | |
| US20240025908A1 (en) | Compound used as kinase inhibitor and use thereof | |
| US20230227460A1 (en) | Fused aza-heterocyclic amide compound and use thereof | |
| CN110003204B (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
| KR20240021239A (ko) | Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도 | |
| KR20220054695A (ko) | 퀴나졸린 유도체 | |
| JP4622047B2 (ja) | 新規なヘテロ環カルボキサミド誘導体 | |
| CN115197202B (zh) | 一种ezh2共价抑制剂及其制备方法和应用 | |
| CN114423762A (zh) | 大环类衍生物及其制备方法和用途 | |
| CN112341390B (zh) | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 | |
| WO2023143210A1 (zh) | 一种酞嗪酮类化合物、其制备方法、包含其药物组合物及其应用 | |
| WO2023030335A1 (zh) | 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法 | |
| JP7110335B2 (ja) | プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体 | |
| JP2023527204A (ja) | ３，４－ジヒドロイソキノリン系化合物及びその使用 | |
| CN112159392B (zh) | 取代嘧啶化合物及其药物组合物和该化合物的用途 | |
| CN113354630B (zh) | 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |